NASH/MASH | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

4,365 results for “NASH/MASH”

Trials

View all 3631 →

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

2,150 participants · First posted Jul 30, 2024

Active, not recruiting

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

700 participants · First posted Dec 8, 2023

A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )

80 participants · First posted Dec 29, 2025

Drugs

View all 53 →

MASH(Repair)

NASH therapeutic

saRNA therapeutics (NASH)

Organizations

View all 14 →

Mister Car Wash

United States

Galmed Pharmaceuticals

Israel

Ash Stevens LLC

United States

News

View all 667 →

Madrigal Pharmaceuticals Reports Strong Rezdiffra Launch and Clinical Progress in NASH/MASH

Madrigal Pharmaceuticals Reports Positive Q3 2024 Results and Advances NASH/MASH Programs

Madrigal Pharmaceuticals Reports Strong Rezdiffra Launch and Advancement of NASH Cirrhosis Study

Page 1 of 437